SK bioscience announced positive results from its Phase II clinical trials in infants of its 21-valent pneumococcal conjugate vaccine candidate, ‘GBP410’, evaluating its safety and immunogenicity.
SK bioscience announced positive results from its Phase II clinical trials in infants of its 21-valent pneumococcal conjugate vaccine candidate, ‘GBP410’, evaluating its safety and immunogenicity.